FDA warned Avlon Industries that its over-the-counter drug manufacturing broke quality rules, citing missing identity tests for high-risk glycerin/propylene glycol and validation failures.
What happened
FDA inspected Avlon's drug manufacturing facility in Melrose Park, IL, from January 17 to 24, 2023. FDA found missing identity testing of incoming components (including high-risk glycerin and propylene glycol), no process or cleaning validation, an unqualified and inadequately monitored water system, and inadequate quality-unit oversight. FDA said Avlon's February 13, 2023 response was inadequate.
What FDA found
Avlon did not test each incoming component lot for identity before making OTC drugs and relied on certificates of analysis from unqualified suppliers.
21 CFR 211.84(d)(1) and 211.84(d)(2)Avlon did not test each container of each shipment of high-risk glycerin or propylene glycol for diethylene glycol (DEG) or ethylene glycol (EG).
21 CFR 211.84(d)(1) and 211.84(d)(2)Avlon lacked data to show its OTC drug manufacturing processes were validated to reproducibly yield uniform, quality drugs.
21 CFR 211.100(a) and 211.100(b)Avlon lacked cleaning validation for equipment also used for cosmetics and lacked cleaning and use logs for production tanks; this repeated a 2017 finding.
21 CFR 211.100(a) and 211.100(b)Avlon did not qualify or adequately monitor its water system, including microbial testing, and this repeated a 2017 finding.
21 CFR 211.100(a) and 211.100(b)Avlon's quality control unit did not adequately oversee manufacturing; FDA saw incomplete current good manufacturing practice documents such as policies, written procedures, validation plans, stability program, corrective actions, annual product review, and training.
21 CFR 211.22
What FDA wants
FDA tells Avlon to respond in writing within 15 working days with corrective actions and evidence, including DEG/EG testing and risk assessment, process and cleaning validation fixes, water-system remediation, and quality-unit fixes. FDA also recommends a qualified current good manufacturing practice consultant perform a six-system audit.
Who should pay attention
- companies that buy OTC drug products made at this site
- makers and buyers of glycerin or propylene glycol
- manufacturers sharing drug and cosmetic equipment
This is a summary. Read the original letter on fda.gov.